David Bharucha Sells 12,245 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insider David Bharucha sold 12,245 shares of Milestone Pharmaceuticals stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $1.93, for a total value of $23,632.85. Following the transaction, the insider owned 99,848 shares of the company’s stock, valued at $192,706.64. This represents a 10.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

David Bharucha also recently made the following trade(s):

• On Monday, December 15th, David Bharucha sold 58,007 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.32, for a total value of $134,576.24.

Milestone Pharmaceuticals Stock Performance

Milestone Pharmaceuticals stock opened at $1.89 on Friday. Milestone Pharmaceuticals Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $3.06. The company has a market capitalization of $160.97 million, a price-to-earnings ratio of -2.30 and a beta of 0.44. The stock has a fifty day moving average of $2.23 and a two-hundred day moving average of $1.96. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.05. On average, analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current fiscal year.

Key Stories Impacting Milestone Pharmaceuticals

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone announced U.S. pharmacy availability of its CARDAMYST nasal spray — a commercial launch that begins the company’s transition from development to product revenue and increases commercial visibility. Read More.
• Positive Sentiment: Zacks Research upgraded MIST from “Hold” to “Strong Buy,” which can attract short‑term buyers and momentum flows into a thinly traded microcap. Read More.
• Neutral Sentiment: Technical/trading context is mixed: shares sit below the 50‑day moving average and current volume is below the stock’s average, which may limit a sustained rally despite the launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto executed large sales (133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93). Material insider reductions by the CEO often trigger investor concern about insider conviction and can add selling pressure. Read More.
• Negative Sentiment: Other senior insiders (COO Jeffrey Nelson, and executives David Bharucha and Lorenz Muller) also sold large blocks on Dec. 15 and Jan. 26, representing double‑digit percentage cuts to their stakes—a clustered pattern that intensifies negative sentiment and helps explain downward pressure on the share price. Read More. Read More. Read More.

Institutional Trading of Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in MIST. Propel Bio Management LLC raised its position in shares of Milestone Pharmaceuticals by 186.1% in the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after buying an additional 3,333,333 shares during the period. Orbimed Advisors LLC acquired a new stake in Milestone Pharmaceuticals during the third quarter worth about $6,444,000. Simplify Asset Management Inc. raised its holdings in shares of Milestone Pharmaceuticals by 186.2% in the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after purchasing an additional 1,842,974 shares during the period. Pathstone Holdings LLC purchased a new position in shares of Milestone Pharmaceuticals in the 3rd quarter worth about $2,000,000. Finally, Boxer Capital Management LLC acquired a new position in shares of Milestone Pharmaceuticals in the 3rd quarter valued at about $1,333,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MIST. Zacks Research raised shares of Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday. TD Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. Wall Street Zen lowered Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Finally, Wells Fargo & Company upped their target price on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Milestone Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.